NYSE:CANF Can-Fite BioPharma (CANF) Stock Price, News & Analysis $3.71 +0.19 (+5.40%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$3.50▼$3.8650-Day Range$2.29▼$4.4952-Week Range$1.81▼$4.69Volume132,565 shsAverage Volume51,847 shsMarket Capitalization$13.13 millionP/E RatioN/ADividend YieldN/APrice Target$18.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsTrends Get Can-Fite BioPharma alerts: Email Address Can-Fite BioPharma MarketRank™ Stock AnalysisAnalyst RatingStrong Buy3.50 Rating ScoreUpside/Downside385.2% Upside$18.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.29) to ($1.11) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.00 out of 5 starsMedical Sector690th out of 936 stocksPharmaceutical Preparations Industry321st out of 436 stocks 3.8 Analyst's Opinion Consensus RatingCan-Fite BioPharma has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageCan-Fite BioPharma has only been the subject of 2 research reports in the past 90 days.Read more about Can-Fite BioPharma's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for CANF. Previous Next 0.0 Dividend Strength Dividend YieldCan-Fite BioPharma does not currently pay a dividend.Dividend GrowthCan-Fite BioPharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CANF. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Can-Fite BioPharma this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for CANF on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.MarketBeat Follows6 people have added Can-Fite BioPharma to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Can-Fite BioPharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.80% of the stock of Can-Fite BioPharma is held by insiders.Percentage Held by InstitutionsOnly 21.00% of the stock of Can-Fite BioPharma is held by institutions.Read more about Can-Fite BioPharma's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Can-Fite BioPharma are expected to grow in the coming year, from ($1.29) to ($1.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Can-Fite BioPharma is -2.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Can-Fite BioPharma is -2.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCan-Fite BioPharma has a P/B Ratio of 2.11. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Oxford ClubDon't Pay a Dime for Marc Lichtenfeld's Top AI PicksUsually, you'd have to plunk down a hefty sum to get your hands on Marc Lichtenfeld's latest income research... But today, the author of Get Rich with Dividends is feeling extra generous...Click here now to claim your FREE copy of Marc's AI playbook. About Can-Fite BioPharma Stock (NYSE:CANF)Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.Read More CANF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CANF Stock News HeadlinesJuly 20, 2024 | americanbankingnews.comCan-Fite BioPharma (NYSE:CANF) Now Covered by Analysts at StockNews.comJuly 18, 2024 | americanbankingnews.comCan-Fite BioPharma (NYSE:CANF) Rating Increased to Strong-Buy at EF Hutton Acquisition Co. IJuly 27, 2024 | Crypto 101 Media (Ad)Next opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has led to a massive bull run in the year after it happens. That means we're in the "golden window" right now…July 17, 2024 | globenewswire.comJoin Can-Fite's Exclusive Live Investor Webinar and Q&A Session on August 8July 11, 2024 | globenewswire.comCan-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic CancerJune 24, 2024 | businesswire.comCan-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the LiverJune 10, 2024 | businesswire.comCan-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa StudyJune 5, 2024 | businesswire.comCan-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 StudyJuly 27, 2024 | Crypto 101 Media (Ad)Next opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has led to a massive bull run in the year after it happens. That means we're in the "golden window" right now…May 29, 2024 | businesswire.comIndependent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart DiseasesMay 27, 2024 | finance.yahoo.comCan-Fite to Participate in Partnering Meetings at Bio International Convention 2024May 27, 2024 | businesswire.comCan-Fite to Participate in Partnering Meetings at Bio International Convention 2024May 23, 2024 | finance.yahoo.comJoin Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on June 6May 23, 2024 | businesswire.comJoin Can-Fite's Exclusive Live Investor Webinar and Q&A Session on June 6May 13, 2024 | businesswire.comCan-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer StudyMay 10, 2024 | finanznachrichten.deCan-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TVMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Can-Fite BioPharma on IND Clearance and Positive Clinical Study OutlookMay 6, 2024 | businesswire.comCan-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602See More Headlines Receive CANF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Can-Fite BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/30/2021Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:CANF CUSIPN/A CIK1536196 Webwww.canfite.com Phone972-3-924-1114Fax972-3924-9378Employees8Year FoundedN/APrice Target and Rating Average Stock Price Target$18.00 High Stock Price Target$18.00 Low Stock Price Target$18.00 Potential Upside/Downside+374.9%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,630,000.00 Net Margins-1,027.46% Pretax Margin-1,027.46% Return on Equity-113.75% Return on Assets-69.91% Debt Debt-to-Equity RatioN/A Current Ratio4.91 Quick Ratio4.90 Sales & Book Value Annual Sales$743,000.00 Price / Sales18.06 Cash FlowN/A Price / Cash FlowN/A Book Value$1.76 per share Price / Book2.15Miscellaneous Outstanding Shares3,540,000Free Float3,512,000Market Cap$13.42 million OptionableNot Optionable Beta1.45 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Pnina Fishman Ph.D. (Age 76)Founder, Chief Scientific Officer & Executive Chairperson Comp: $630kMr. Motti Farbstein (Age 60)CEO and Chief Financial & Operating Officer Comp: $423kDr. Sari Fishman Ph.D. (Age 52)Vice President of Business Development Comp: $340kDr. Ilan Cohn Ph.D. (Age 70)Co-Founder & Director Dr. Stephen A. Harrison FACPM.D., Member of Clinical Advisory Board & Consulting Chief Medical OfficerKey CompetitorsDURECTNASDAQ:DRRXReneo PharmaceuticalsNASDAQ:RPHMLantern PharmaNASDAQ:LTRNCarisma TherapeuticsNASDAQ:CARMKezar Life SciencesNASDAQ:KZRView All Competitors CANF Stock Analysis - Frequently Asked Questions How have CANF shares performed this year? Can-Fite BioPharma's stock was trading at $2.20 at the beginning of 2024. Since then, CANF stock has increased by 68.6% and is now trading at $3.71. View the best growth stocks for 2024 here. How were Can-Fite BioPharma's earnings last quarter? Can-Fite BioPharma Ltd. (NYSE:CANF) announced its quarterly earnings results on Tuesday, November, 30th. The company reported ($1.90) earnings per share for the quarter, missing analysts' consensus estimates of ($0.90) by $1.00. The firm earned $0.25 million during the quarter. Can-Fite BioPharma had a negative net margin of 1,027.46% and a negative trailing twelve-month return on equity of 113.75%. When did Can-Fite BioPharma's stock split? Can-Fite BioPharma shares reverse split before market open on Monday, January 9th 2023. The 1-10 reverse split was announced on Monday, January 9th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Can-Fite BioPharma? Shares of CANF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:CANF) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Can-Fite BioPharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Can-Fite BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.